Kornimate/medical-research-clean huggingface dataset:
effect of iron and folic acid on skin fungal pattern in patients with arsenicosis

Conditions: Chronic Arsenic Poisoning

Summary: this study will be conducted to observe any change in fungal pattern on skin of arsenicosis patients before and after administration of iron (150 mg) and folic acid (0.5 mg) tablets.

arsenicosis is remaining as a precarious issue in bangladesh for the last few decades. the fact of resentment is that this perilous condition still remains unresolved worldwide. so, it has become the demand of era to address this issue. different diseases are manifested in different way. in arsenicosis melanosis and keratosis are the most common manifestations. the actual mechanism of development of keratosis is unclear. chronic ingestion of arsenic contaminated water causes accumulation of arsenic in keratin rich tissues like skin, hair, nail and producing characteristic skin manifestations like melanosis and keratosis. metabolism of arsenic depends on folate pathway and dietary deficiency of folic acid reduced the total arsenic excretion and leads to development of cancer. in different study results shown that folic acid reduces the blood arsenic level. as arsenicosis is a chronic disease condition, fungal infection is more common to them. moreover the skin fungal pattern in arsenicosis yet not known. therefore, this study will be conducted to determine is there any change in skin fungal pattern in patients with palmar arsenical keratosis before and after administration of iron and folic acid. forty two patients with palmar arsenical keratosis will be recruited on the basis of inclusion and exclusion criteria. twenty one patients will be furnished tablet placebo once daily for 12 weeks without any interruption. another twenty one patients will be furnished iron (150 mg) and folic acid (0.5 mg) once daily for 12 weeks without any interruption. water and nail samples will be collected for confirming the diagnosis. skin sample will be collected two times (before and after giving iron and folic acid) for qualitative analysis of fungi. so, this study will determine any change in fungal pattern after administrating tablet iron and folic acid.

Eligibility criteria:
inclusion criteria: (patients) * history of drinking arsenic contaminated water(\>50 μg/l) for more than 6 months * patients having moderate palmar keratosis * patients those voluntarily agree to participate exclusion criteria: * pregnant and lactating mother * any other chronic diseases like tuberculosis, diabetes mellitus, asthma * patient under treatment of arsenicosis on criteria:
lateral rectus muscle and anterior segment optical coherence tomography (as-oct)

Conditions: Intermittent Exotropia

Summary: •background and study aims : the investigators conducted this study to evaluate the movement of extraocular muscle after strabismus surgery with non-invasive tool called as-oct. * who can participate? patients who underwent typical lateral rectus recession surgery for correcting intermittent exotropia * what does the study involve? volunteers will attend a clinic for four visits over six months. they will undergo as-oct at every visits during follow up period. as-oct is non-invasive test to evaluate operation site. the test only requires their cooperation when they undergo as-oct. * what are the possible benefits and risks of participating? this is non-invasive test for your postoperative follow up. therefore, there will be no risks about this test. * where is the study run from? samsung medical center * when is the study starting and how long is it expected to run for? from feb 2014 to dec 2014

the aim of this study is 1) to evaluate the reliability and accuracy of as-oct in the measurement of the lateral rectus (lr) insertion distance, 2)to investigate the longitudinal change of lr muscle insertion after strabismus surgery, and 3)to determine the effect of insertion movement on the angle of deviation after strabismus surgery. an as-oct scan of the lr muscle was performed every visits. preoperative limbus-lr insertion distance was compared with intraoperative surgical caliper measurement of lr insertion using intraclass correlation coefficient analysis (icc). data on gender, age, degree of deviation (prism diopter), and spur-lr insertion distance using as-oct were collected at postoperative months 1,3 6.

Eligibility criteria:
inclusion criteria: * patients who underwent lateral rectus recession surgery for correcting intermittent exotropia exclusion criteria: * previous ocular surgery * other ocular diseases except intermittent exotropia * amblyopia
role of plasma rich growth factor in repair primary cleft palate

Conditions: Cleft Palate; Plasma Rich in Growth Factors

Summary: does the plasma-rich growth factor (prgf) with primary cleft palate repair accelerate wound healing and prevent post-operative oronasal fistula occurrence?

the primary objective is to assess and evaluate the improvement of wound healing (edema at 5th day post operatively) as a primary outcome, and secondary objective is to assess and evaluate the wound closure and the decreasing of the occurrence of the oronasal fistula as a secondary outcome among children with cleft palate, using plasma rich growth factor between nasal mucosa and palatal mucosa

Eligibility criteria:
inclusion criteria: * systemically healthy patients (american society of anesthesiologists -asa i and ii); not older than 6-18 months * patients with primary non-syndromic isolated cleft palate * apprehensive to be in the study. exclusion criteria: * patients with recurrent palatal fistula * existence of syndromic cleft palate * blood diseases and platelet disorders (hematological disease) * systematic disease radiotherapy or chemotherapy for malignancy

Keywords: cleft palate plasma rich growth factor healing
colchicine for patients with chagas´ disease( b1 stage)

Conditions: Chagas Disease; Colchicine Resistance

Summary: this study evaluate the addition of colchicine in the treatment of patients with chagas´disease. forty patients will receive colchicine while twenty patients will receive placebo

chagas disease is considered one of the main cause of dilated cardiomyopathy in latin america. the histopathological characteristics of chagas' disease are the presence of myocarditis, destruction of heart fibers, and severe myocardial fibrosis. colchicine had a protective effect on myocardium, indicated by decreased interstitial myocardial fibrosis and attenuated myocardial inflammation. it is an inflammatory cause of cardiomyopathy and myocardial fibrosis is the hallmark of this disease. colchicine is a drug used in inflammatory diseases, and could also act on myocardial remodeling interfering in the synthesis of collagen

Eligibility criteria:
inclusion criteria: * clinical and serological diagnosis of chagas´disease ( stage b1) * must be able to swallow tablets exclusion criteria: * myocardial infarction or coronary artery disease, * diabetes mellitus, * valvular disease, * creatinine clearance \<30 ml / kg / min * contraindication to perform cardiac magnetic resonance imaging * use of angiotensin converting enzyme inhibitors, angiotensin ii receptor blockers and aldosterone blockers * previous use of benzonidazole

Keywords: fibrosis inflammation
effectiveness of dry needling adjuvant to selective serotonin reputake inhibitors vs tp injection for pain management

Conditions: Pain; Fibromyalgia

Summary: the principal objective is to contribute valuable insights that hold direct implications for medical practice and patient care, with the potential to influence health policy pertaining to fibromyalgia management.

the study aims to outline distinct patient subgroups manifesting heightened responsiveness to one therapeutic intervention vis-à-vis the other, thereby facilitating the formulation of more personalized and efficacious treatment modalities.

Eligibility criteria:
inclusion criteria: * stable on ssris for at least three months (for group a) * age between 18 and 65 years * participants suffering from recent cervical pain without any pathology exclusion criteria: * presence of any other chronic pain conditions. * contraindications to ssris or trigger point injections. * pregnancy or lactation. * history of psychiatric disorders other than depression and anxiety
effect of radial extracorporeal shockwave therapy on ultrasonography changes in patients with iliotibial band syndrome

Conditions: Iliotibial Band Syndrome

Summary: this study will be conducted to investigate the effects of radial extracorporeal shockwave therapy on ultrasonography changes, pain intensity, pain pressure threshold and lower limb function in patient with iliotibial band syndrome

iliotibial band syndrome is an overuse injury that affect the lateral aspect of the knee. it is common in endurance sport activities such as running and cycling. it is the most common running injury of the lateral knee. itbs is a non-traumatic overuse injury caused by friction/rubbing of the distal portion of the iliotibial band (itb) over the lateral femoral epicondyle with repeated flexion and extension of the knee. females are twice as likely to sustain itbs compared to male due to sex differences in frontal and transverse plane hip and knee joint angles.an alternative treatment strategy of itbs is radial extracorporeal shockwave therapy (reswt). it is considered safe as it results in minor adverse effects including worsening of symptoms over a short period, reversible local swelling, redness and hematoma. reswt has also shown to be effective in the treatment of several chronic musculoskeletal pain conditions such as lateral epicondylitis, achilles tendinopathy, plantar fasciitis, patellar tendinopathy, calcific tendinitis of the shoulder and chronic proximal hamstring tendinopathy. sixty patients with iliotibial band syndrome will be assigned randomly to two groups; the first one will receive radial extracorporeal shockwave and traditional therapy, the second one will receive traditional therapy alone.

Eligibility criteria:
inclusion criteria: * sixty patients suffer from itbs. * the age of patients ranges from (18-55) years. exclusion criteria: * signs or symptoms of other pathologies of the knee. * previous treatment for itbs in the last 6 months. * use of nsaid's or analgesics later than two weeks before baseline. * previous surgery on the affected knee. * pregnancy. * rheumatic disease. * previous shockwave treatment

Keywords: iliotibial band syndrome radial extracorporeal shockwave ultrasonography changes
experiences of a home-based virtual reality serious game in people with chronic non-specific neck pain

Conditions: Chronic Non-specific Neck Pain

Summary: background: immersive virtual reality (vr) has been used for several years in the treatment of chronic neck pain. this new type of rehabilitation device, which can be used at home, is promising and seems to be as effective as conventional treatments for neck pain. exploring the experience of people with chronic neck pain using this type of rehabilitation device at home could, among other things, help to understand the factors favoring good adherence and those not favoring it. this could also help us to improve vr home rehabilitation programs according to the patients' needs, preferences and expectations. however, currently, no studies have qualitatively evaluated the experience of people with chronic non-specific neck pain using an immersive vr serious game at home. objective: to explore the experience of people with chronic non-specific neck pain who used an immersive vr serious game at home. methods: individual semi-structured interviews will be conducted with people with chronic non-specific neck pain. interviews will last for approximately 30 to 60 minutes and will be carried out face-to-face or via videoconference (microsoft teams), depending on up-to-date guidance relating to the covid-19 pandemic. semi-structured interviews will be audio-recorded and transcribed verbatim. the transcripts will be read several times and analyzed using thematic analysis, with themes emerging from the transcripts (inductive approach). these themes will be defined and revised throughout the analysis process. discussion: study findings will help to better understand the experience of people with chronic non-specific neck pain using a vr serious game at home, and then will allow to adapt it to the subjects' needs, preferences and expectations. these adaptations could further increase adherence to treatment and/or improve clinical outcomes for people with chronic non-specific neck pain using this type of rehabilitation device at home.


Eligibility criteria:
inclusion criteria: * adults (over 18 years), men or women, living in belgium * chronic (\> 3 months) non-specific neck pain (no specific cause responsible for the neck pain) * to speak fluent french and to be able to provide informed consent to take part in an interview * to be able to take part in a semi-structured interview * no susceptibility to motion sickness, according to the motion sickness susceptibility questionnaire (mssq) exclusion criteria: * age under 18 years * specific cause responsible for the neck pain (cancer, fracture, etc.) * signs of sensorimotor dysfunction (dizziness, vestibular disorders) * susceptibility to motion sickness, according to the mssq * vision problems * altered comprehension or inability to speak fluent french * inability to provide written informed consent or to take part in a semi-structured interview
mr-targeted vs. random trus-guided prostate biopsy

Conditions: Prostate Cancer

Summary: to compare prostate cancer (pca) detection rate of magnetic resonance (mr)-targeted biopsy and transrectal ultrasound (trus)-guided biopsy in patients with high psa values and at least one previous negative prostate biopsy. subjects will be submitted to a multiparametric mr scan of the prostate and subsequently patients with a suspicious mr for pca presence will be randomized (1:1) into the two study arms.

in men with previously negative prostate biopsy and persistent elevated psa value, it is unclear which biopsy strategy offers the highest detection rate for significant pca. the hypothesis of this study is that mr-targeted biopsy improves the detection rates of significant prostate cancers compared with systematic trus-guided prostate biopsy. men with at least one previously negative trus-guided biopsy and persistently elevated psa values (\> 4 ng/ml) will be submitted to a multiparametric mr imaging examination of the prostate. subsequently, participants with suspected regions at mr imaging will be randomized (1:1) into the two study arms. in study arm a patients will be submitted to mr-targeted in-bore prostate biopsy based on the multiparametric mr imaging findings. in study arm b patients will be submitted to systematic trus-guided prostate biopsy with saturation scheme.

Eligibility criteria:
inclusion criteria: * men aged 50-80 * at least one negative trus-guided prostate biopsy * psa \> 4 ng/ml * at least one suspected region detected at multiparametric mr imaging * signed informed consent exclusion criteria: * known prostate cancer diagnosis * contraindication against mr imaging or uncooperative patients

Keywords: multiparametric magnetic resonance imaging mr-targeted prostate biopsy saturation trus-guided prostate biopsy
safety study of s.flexneriza-s.sonnei bivalent conjugate vaccine in healthy volunteers aged above 3 months

Conditions: Dysentery; Dysentery, Bacillary

Summary: the purpose of this study is to evaluate safety of s.flexneriza-s.sonnei bivalent conjugate vaccine in healthy volunteers aged above 3 months.


Eligibility criteria:
inclusion criteria: * 3 months old and above healthy people. * subject or legal representative who consent and has signed written informed consent. * subject and parent/guardian who is able to comply with all study procedures. * subject who did't receive blood products within 30 days ,immune with any live vaccine within 14 days and inactivated vaccine within 7 days before vaccination. * axillary temperature ≤37.0 ℃. exclusion criteria: * febrile illness (temperature ≥ 38°c) in the 3 days. * subject who are allergic to tetanus toxoid. * allergic history after vaccination. * immunodeficiency diseases patients who administered with immunosuppressive agents. * in pregnancy or lactation or pregnant women. * subject who are suffering from serious chronic diseases, infectious diseases, active infection, cardiovascular disease,liver or kidney disease. * subject who have symptoms such as diarrhea, abdominal pain, and pus and bloody stools in the past 3 days. * history of allergy，eclampsia, epilepsy,brain trauma,encephalopathy and mental disease or family disease. * subject who diagnosis of thrombocytopenia or other history of coagulopathy may cause intramuscular contraindication. * children with abnormal labor（pregnancy week\ 42w）,birth weight (\ 4000g), asphyxia rescue history,congenital malformations or developmental disorders(only applicable to 3-5 months old group) * blood routine, blood chemistry and urinalysis laboratory collection abnormalities and the severity of grade 2 and above before immunization. * subject who plan to participate in or is in any other drug clinical trial. * any condition that, in the judgment of investigator, may affect trial assessment.
ath-1017 treatment in subjects with parkinson's disease dementia or dementia with lewy bodies (shape trial)

Conditions: Parkinson Disease Dementia; Dementia With Lewy Bodies

Summary: this study is designed to evaluate the safety and treatment effects of fosgonimeton (ath-1017) in subjects with parkinson's disease dementia or dementia with lewy bodies, with a randomized treatment duration of 26 weeks.

the study is designed to evaluate the safety and treatment effects of ath-1017 in subjects with parkinson's disease dementia or dementia with lewy bodies, with a randomized, double-blind, placebo-controlled, parallel-arm treatment duration of 26 weeks.

Eligibility criteria:
inclusion criteria: * subjects with confirmed diagnosis of parkinson's disease or dementia with lewy bodies * moca score 11 to 23, inclusive, at screening * probable parkinson's disease dementia or lewy body dementia * bmi between ≥ 16and ≤ 35 kg/m2 for females and between≥ 18 and ≤ 35 kg/m2 for males at screening * reliable and capable support person/caregiver, who is willing to accept responsibility for supervising the treatment or, if required, administering study drug, and assessing the condition of the subject throughout the study in accordance with all protocol requirements exclusion criteria: * hoehn-yahr stage 5 * history of significant neurological disease other than pdd or dlb that may affect cognition at onset of dementia * subjects on deep brain stimulation * history of brain mri scan indicative of any other significant abnormality * history of unexplained loss of consciousness, and epileptic fits * hearing test result considered unacceptable for auditory erp p300 assessment * diagnosis of severe major depressive disorder even without psychotic features (gds score \[15-item scale\] \>7 at screening) * significant suicide risk based on c-ssrs * significant psychosis (according to diagnostic and statistical manual of mental disorders) * moderate or severe substance abuse disorder (according to dsm-5) * myocardial infarction or unstable angina within the last 6 months * clinically significant cardiac arrhythmia (including atrial fibrillation), cardiomyopathy, or cardiac conduction defect (note: pacemaker is acceptable) * clinically significant ecg abnormality at screening * chronic kidney disease (egfr \< 45 ml/min using cockcroft-gault formula) * hepatic impairment with alanine aminotransferase or aspartate aminotransferase \> 2 times the upper limit of normal, or child-pugh class b and c * malignant tumor within 3 years before screening * memantine at any dose or combination * donepezil at 23 mg

Keywords: parkinson's disease dementia dementia with lewy bodies dementia hgf/met hepatocyte growth factor neurotrophic ath-1017 event-related potential erp p300
uptake of comprehensive eye examination trial

Conditions: Glaucoma; Diabetic Retinopathy

Summary: 1. to evaluate a educational intervention promoting acceptance of comprehensive eye examination in rural guangdong. 2. to evaluate the impact of acceptance of comprehensive eye examination in rural guangdong.

a comprehensive eye examination includes visual acuity, slitlamp exam, pupil exam, intraocular pressure, gonioscope lens and 90d lens with slitlamp exam fundus. a number of eye diseases are irreversible at on early stage. both glaucoma and diabetic retinopathy(dr)are frequently asymptomatic until significant, often-irreversible, damage to the vision has already occurred. it has been estimated that only 10% of persons in india with glaucoma are diagnosed, and the handan eye survey reports that only 10% of persons with diabetes in rural areas of china have received diabetic eye care. in order to deliver effective care for dr and glaucoma in areas with limited resources, education of patients and interventions to promote compliance among patients will both be needed.

Eligibility criteria:
inclusion criteria: * age ≥40 years who have never had a comprehensive eye examination exclusion criteria: * inability to join informed consent

Keywords: comprehensive eye examination acceptance glaucoma diabetic retinopathy
a relative bioavailability study of bupropion hci 150 mg sustained-release tablets under fasting conditions

Conditions: Depression

Summary: the purpose of this study is to demonstrate the relative bioequivalence of bupropion hci 150 mg sr tablets under fasting conditions.


Eligibility criteria:
inclusion criteria: * no clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening. exclusion criteria: * positive test results for hiv or hepatitis b or c. * treatment for drug or alcohol dependence.